Director's Dealing

RNS Number : 4891B

Ergomed plc

11 February 2022

 

Ergomed plc
 

Director's Dealing

Guildford, UK - 11 February 2022 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that   on 11 February 2022, Dr Miroslav Reljanović, Executive Chairman of Ergomed, transferred 150,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to an employee of the Company.  The transfer took place following an exercise of options under an option agreement dated 30 November 2016 between Dr Reljanović and the relevant employee and the exercise price was 1p per ordinary share.

Following the transfer, Dr Reljanović holds 9,529,297 ordinary shares representing 19.39 % of the Company's issued share capital.

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Miroslav Reljanović
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Transfer of shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.01	150,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	150,000 £0.01 £1,500
f)	Date of the transaction	11 February 2022
g)	Place of the transaction	London Stock Exchange, AIM

ENDS

Enquiries :

Ergomed plc       Tel: [phone]

Dr Miroslav Reljanović (Executive Chairman) 

Richard Barfield (Chief Financial Officer) 

Numis Securities Limited   Tel: [phone]

Freddie Barnfield / Euan Brown (Nominated Adviser) 

James Black (Broker) 

Peel Hunt LLP   Tel: [phone]

James Steel / Dr. Christopher Golden

Consilium Strategic Communications  Tel: [phone]

Chris Gardner / Matthew Neal                                                   [e-mail]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

 

END

 

 

DSHEAKAFFEDAEFA